Trial · NCT01929460
A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
NCT01929460, Not applicable, Completed, Kaiser Permanente; results first posted 2015-12-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration. Trials, record NCT01929460. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01929460
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
- NCT number
- NCT01929460
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 26 participants, actual
- Lead sponsor
- Kaiser Permanente
- Conditions
- Pancreatic Cysts
- Interventions
- Ciprofloxacin, Placebo (for ciprofloxacin)
- First posted
- 2013-08-28
- Last updated
- 2016-02-15
- Results first posted
- 2015-12-31
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | At 2 weeks after procedure | first time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration) |
| Primary | Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | At 4 weeks after procedure | second time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration) |
| Primary | Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | At 6 weeks after procedure | third and final time point (number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration) |
| Secondary | Adverse Drug Reactions | six weeks | Number of participants with adverse drug reactions |
| Secondary | Procedure-related Complications | six weeks after procedure | Number of patients with procedure-related complications |
| Secondary | Mean Cyst Fluid Carcinoembryonic Antigen (CEA) | six weeks | Mean cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions |
| Secondary | Mean Cyst Fluid Amylase | six weeks | Mean cyst fluid amylase for classification of mucinous cystic lesions |
| Secondary | Median Cyst Fluid Carcinoembryonic Antigen (CEA) | six weeks | Median cyst fluid carcinoembryonic antigen (CEA) for classification of mucinous cystic lesions |
| Secondary | Median Cyst Fluid Amylase | six weeks | Median cyst fluid amylase for classification of mucinous cystic lesions |
Source ClinicalTrials.gov
Outcomes9
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | At 2 weeks after procedure | participants | NUMBER | |
| PRIMARY | Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | At 4 weeks after procedure | participants | NUMBER | |
| PRIMARY | Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | At 6 weeks after procedure | participants | NUMBER | |
| SECONDARY | Adverse Drug Reactions | six weeks | participants | NUMBER | |
| SECONDARY | Procedure-related Complications | six weeks after procedure | participants | NUMBER | |
| SECONDARY | Mean Cyst Fluid Carcinoembryonic Antigen (CEA) | six weeks | ng/mL | MEAN | |
| SECONDARY | Mean Cyst Fluid Amylase | six weeks | Units/L | MEAN | |
| SECONDARY | Median Cyst Fluid Carcinoembryonic Antigen (CEA) | six weeks | ng/mL | MEDIAN | |
| SECONDARY | Median Cyst Fluid Amylase | six weeks | Units/L | MEDIAN |
Source ClinicalTrials.gov
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Ciprofloxacin (Standard Group) | 0 | participants | ||
| Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Placebo (Intervention Group) | 0 | participants | ||
| Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Ciprofloxacin (Standard Group) | 0 | participants | ||
| Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Placebo (Intervention Group) | 0 | participants | ||
| Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Ciprofloxacin (Standard Group) | 0 | participants | ||
| Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Placebo (Intervention Group) | 0 | participants | ||
| Adverse Drug Reactions | Ciprofloxacin (Standard Group) | 0 | participants | ||
| Adverse Drug Reactions | Placebo (Intervention Group) | 0 | participants | ||
| Procedure-related Complications | Ciprofloxacin (Standard Group) | 0 | participants | ||
| Procedure-related Complications | Placebo (Intervention Group) | 5 | participants |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ciprofloxacin (Standard Group) | 13 | |
| Overall Study | STARTED | Placebo (Intervention Group) | 13 | |
| Overall Study | COMPLETED | Ciprofloxacin (Standard Group) | 13 | |
| Overall Study | COMPLETED | Placebo (Intervention Group) | 13 | |
| Overall Study | NOT COMPLETED | Ciprofloxacin (Standard Group) | 0 | |
| Overall Study | NOT COMPLETED | Placebo (Intervention Group) | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | pain | Gastrointestinal disorders | Drug (Standard Group) | 0 | 13 | 0 |
| other | pain | Gastrointestinal disorders | Intervention Group | 4 | 13 | 4 |
| serious | pancreatitis | Gastrointestinal disorders | Drug (Standard Group) | 0 | 13 | 0 |
| serious | pancreatitis | Gastrointestinal disorders | Intervention Group | 1 | 13 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Drug (Standard Group) | ||
| Total, all-cause mortality | Intervention Group | ||
| Total, other adverse events | Drug (Standard Group) | 0 | 13 |
| Total, other adverse events | Intervention Group | 4 | 13 |
| Total, serious adverse events | Drug (Standard Group) | 0 | 13 |
| Total, serious adverse events | Intervention Group | 1 | 13 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Trial comparisons |
| Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Trial comparisons |
| Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Adverse Drug Reactions | Trial comparisons |
| Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration | Trial comparisons |
| Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Procedure-related Complications | Trial comparisons |
| Drug (Standard Group) vs Intervention Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01929460
GET https://conductscience.org/api/trials/v1/NCT01929460/registered